Based on the BCG Digital Ventures-Boston Consulting Group’s just issued 2022 Future of Digital Health: Health Care Innovation Predictions, the group expects 2022 to continue the trends seen over the last two years. Focus on “care anywhere” will support a continued increase in telemedicine use and, with it, advances in home-based testing, diagnostics and monitoring devices.

Cancer diagnostics company Biofidelity Ltd. reported a $23 million series A+ investment round, led by Octopus Ventures with participation from SBI Investment Co. Ltd. and existing investors. Funds will be used for the commercial launch of the company’s first commercial assay Asypre-Lung. The oncology panel is designed to detect DNA mutations from tissue or liquid biopsy quicker than current approaches like gene sequencing.